Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer is a research paper published in Journal of Pharmaceutical Analysis (2024). On theSindex it has a DataRank of 0.312. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: R01CA237027
National Cancer Institute
Grant: R43CA275410
National Cancer Institute
Grant: P30CA016056
National Cancer Institute
Grant: R44CA176937
National Cancer Institute
Grant: R01CA240290
Pancreatic Cancer Action Network
Grant: 23-CAT-LIFZ
National Institutes of Health
Grant: 5R01CA237027-03
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC
National Institutes of Health
Grant: 5P30CA016056-40
Roswell Park Cancer Institute Cancer Center Support Grant
National Institutes of Health
Grant: 5R44CA176937-03
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer
National Institutes of Health
FWCI
1.12
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals